Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Viekira Pak
Financials
AbbVie's Mavyret takes a big bite from Gilead's hep C guidance
Thanks to new competition from AbbVie, Gilead's important hep C franchise will have another rough year in 2018.
Eric Sagonowsky
Feb 7, 2018 9:46am
Merck to high-risk military veterans: Get a hep C education
Oct 16, 2017 9:15am
AbbVie's pan-genotypic hep C drug Mavyret undercuts competition
Aug 3, 2017 5:21pm
AbbVie scores surprisingly good Q2 results but pipeline worries persist
Jul 28, 2017 12:29pm
Gilead CEO touts new M&A scout amid clamor for deals
May 3, 2017 11:01am
Look out, GSK: Advair is Express Scripts' next cost-savings target
May 3, 2017 8:29am
